Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin

Journal of Clinical Virology

Volumn 39, Issue 4, 2007, Pages 288-294

  Boo, Irene ^a   Fischer, Alexandra E ^b   Johnson, Doug ^b   Chin, Ruth ^b   Giourouki, Maxine ^b   Bharadwaj, Mandvi ^c   Bowden, Scott ^d   Torresi, Joseph ^b   Drummer, Heidi ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Antivirals; Humoral immunity; Liver disease; Viral hepatitis

Indexed keywords

NEUTRALIZING ANTIBODY; PEGINTERFERON; RIBAVIRIN; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; NEUTRALIZATION TESTS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RIBAVIRIN; VIRAL ENVELOPE PROTEINS;

EID: 34447546703     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.04.019     Document Type: Article

References (24)

1. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100 24 (2003) 14199-14204
2. Baumert T.F., Wellnitz S., Aono S., Satoi J., Herion D., Tilman Gerlach J., et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology 32 3 (2000) 610-617
3. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., and Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 2 (2000) 346-355
4. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 8 (1997) 6011-6019
5. Drummer H.E., Maerz A., and Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 546 2-3 (2003) 385-390
6. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 6 (2006) 2654-2664
7. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99 5 (2002) 3081-3086
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
9. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 5 (2004) 346-355
10. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100 12 (2003) 7271-7276
11. Keck Z., Op De Beeck A., Hadlock K.G., Xia J., Li T.-K., Dubuisson J., et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct propertires and biological functions. J Virol 78 17 (2004) 9224-9232
12. Lamonaca V., Missale G., Urbani S., Pilli M., Boni C., Mori C., et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 30 4 (1999) 1088-1098
13. Lasarte J.J., Garcia-Granero M., Lopez A., Casares N., Garcia N., Civeira M.P., et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 28 3 (1998) 815-822
14. Laskus T., Wilkinson J., Gallegos-Orozco J.F., Radkowski M., Adair D.M., Nowicki M., et al. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127 3 (2004) 764-776
15. Lauer G.M., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79 20 (2005) 12979-12988
16. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 10 (2005) 6023-6034
17. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
18. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
19. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 102 (2005) 4560-4565
20. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 3 (1996) 706-714
21. Ueda E., Enomoto N., Sakamoto N., Hamano K., Sato C., Izumi N., et al. Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29 2 (2004) 89-96
22. Vrolijk J.M., Kwekkeboom J., Janssen H.L., Hansen B.E., Zondervan P.E., Osterhaus A.D., et al. Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. J Infect Dis 188 10 (2003) 1528-1532
23. Youn J.W., Park S.H., Lavillette D., Cosset F.L., Yang S.H., Lee C.G., et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42 6 (2005) 1429-1436
24. Yu M., Bartosch B., Zhang P., Guo Z.P., Renzi P.M., Shen L., et al. Neutralising antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 101 20 (2004) 7705-7710